



HUNTER
POSTGRADUATE
MEDICAL INSTITUTE

30 APRIL 2026

GUT HEALTH UPDATE

[CLICK HERE
TO REGISTER](#)



RSVP

RSVP 28 APRIL 2026

LIVE STREAM

Link will be emailed
afternoon of event



NOTICES

ZOOM NAME

Please make sure your Zoom name is the same that you registered to attend the webinar so that we can note you as attending

OUR PROGRAM

6.30pm	WELCOME & INTRODUCTION CHAIRPERSON	DR MILON SALES, General Practitioner, Bruncker Road General Practice, Adamstown
6.35pm	METABOLIC FATTY LIVER DISEASE	ASSOCIATE PROFESSOR STEVEN BOLLIPO, Gastroenterologist & Hepatologist, Director of Gastroenterology & Endoscopy, John Hunter Hospital
7.15pm	DIAGNOSING AND MONITORING INFLAMMATORY BOWEL DISEASE IN 2026	DR TOM GOODSALL, Staff Specialist Gastroenterology, John Hunter Hospital, and Hunter Gastroenterology, Broadmeadow
8.00pm	FAECAL MICROBIOTA TRANSPLANT UPDATE	DR TOM GOODSALL, Staff Specialist Gastroenterology, John Hunter Hospital, and Hunter Gastroenterology, Broadmeadow
8.30pm	CLOSE	

LEARNING OUTCOMES

- Describe the epidemiology, terminology and clinical impact of Metabolic Dysfunction–Associated Steatotic Liver Disease and its relationship to metabolic risk factors.
- Identify patients at increased risk of MASLD in general practice, including those with Type 2 Diabetes, Hypertension, Dyslipidaemia and features of Metabolic Syndrome.
- Outline appropriate investigation pathways for suspected MASLD, including interpretation of liver function tests and the role of imaging.
- Apply non-invasive risk stratification tools in primary care to identify patients at risk of progressive liver disease such as Nonalcoholic Steatohepatitis, Liver Fibrosis and Cirrhosis.
- Implement evidence-based management strategies including lifestyle modification and optimisation of cardiometabolic risk factors.
- Recognise when specialist referral is indicated for further assessment and management of patients with suspected advanced liver disease.
- Recognise presentations of inflammatory bowel disease
- Classify and interpret investigations of inflammatory bowel disease
- Clarify monitoring and risks of IBD therapy
- Describe the principles and emerging evidence for Fecal Microbiota Transplantation and its role in restoring the gut microbiome.
- Identify current clinical indications for FMT, particularly in the management of recurrent Clostridioides difficile infection.
- Recognise appropriate patient selection and referral pathways for FMT in patients with recurrent or treatment-refractory infection.
- Discuss the potential benefits, risks, and safety considerations associated with FMT, including donor screening and infection control measures.
- Outline emerging research and potential future applications of FMT in conditions such as Inflammatory Bowel Disease, Irritable Bowel Syndrome and metabolic disorders.
- Provide appropriate patient counselling regarding FMT, including expectations, safety considerations, and access to specialist services.

CPD

Activity under the RACGP CPD program
ACRRM Applying for 1 Point per hour

Certificate of Attendance for this meeting provided upon completion of Evaluation Questionnaire



02 4913 8163



Tracy.Dobson@newcastle.edu.au



www.hpmi.org

I am a current HPMI member

I wish to live stream

I am a non HPMI member

I wish pay \$88 to live stream - [click here to pay with credit card](#)

No refunds will be considered for live streaming and recording (if a recording is available)

REGISTRATION DETAILS FOR GUT HEALTH UPDATE

Title

Given name

Surname

Surgery

Name

Address

Phone

Specialty

QA No if GP

Email

Mobile



02 4913 8163



Tracy.Dobson@newcastle.edu.au



www.hpmi.org